Guide · 7 Proven Steps
Avoid Notified Body delays and reduce certification time
MDR certification in 2026 takes 13–18 months on average after a formal application, plus an additional 6–12 months intake queue at the most in-demand Notified Bodies. The fastest route is selecting an NB with current capacity for your device class, submitting a complete technical file at first submission, and starting NB outreach at least 18 months before your target EU launch date. AFINA matching identifies Notified Bodies with current capacity and scope for your specific device — reducing selection time from months to days.
Three factors drive MDR certification timelines: capacity constraints at Notified Bodies (33,175 applications lodged vs. 17,549 certificates issued as of 31 October 2025); scope mismatch — not every NB is designated for every MDR code or device type, forcing manufacturers to restart with a different NB after rejection; and incomplete documentation at first submission — each NB request for additional information pauses the review clock and adds weeks. Of these, only the third is within the manufacturer's direct control before submitting.
BSI is the only NB to have officially published capacity and lead time data — their April 2026 document confirms no capacity restrictions for any device type, with QMS audits within 2 months. NSAI, GMED, and DNV are also reported as accessible with shorter intake queues. TÜV SÜD, TÜV Rheinland, and Dekra are accepting selectively with 6–12 month intake queues before review begins. See the full tracker for current acceptance status:
Begin NB outreach at least 18 months before your planned EU market launch. At the most in-demand NBs, the intake queue alone — before formal review begins — takes 6–12 months. This queue position cannot be recovered once lost. Starting late is the single most common and most avoidable cause of MDR certification delays.
Not every NB is designated for every device type or MDR code — scope mismatch is a leading cause of application rejection and restart. Submit one structured request on AFINA describing your device class, EMDN code, and intended purpose. AFINA routes it to Notified Bodies with active designation and current intake availability for your specific product, and you receive structured responses with estimated timelines.
Each NB request for additional information triggers a clock-stop interruption that pauses the review timeline. Under IR 2026/977 (from February 2027), clock-stops are capped per stage — but a complete first submission eliminates the need for them entirely. Ensure your technical file includes: complete clinical evaluation report, up-to-date risk management file, GSPR checklist with all applicable harmonised standards, and UDI documentation.
Annex IX (QMS audit + technical documentation assessment) and Annex X (EU-type examination) have different timelines. Under IR 2026/977, Annex IX allows the QMS audit and technical documentation review to run in parallel — confirmed as mandatory under Article 2. For Class IIb and III devices, Annex IX with parallel processing is typically faster than sequential Annex X. Choosing incorrectly for your device type forces a pathway change that restarts the clock.
Most NBs offer a pre-application dialogue, and IR 2026/977 encourages structured dialogue in the pre-application phase; it also requires NBs to issue detailed written quotations before the contract (Article 1). Use this stage to confirm the NB's designation covers your device and intended purpose, identify documentation gaps before formal submission, and agree on the audit programme. A good pre-application exchange reduces first-submission rejection risk and shortens the application review phase.
Instead of Annex IX, Class IIa manufacturers may draw up the technical documentation under Annexes II and III and combine it with Annex XI — Part A (production quality assurance) or Part B (product verification) — with the NB assessing the technical documentation of at least one representative device per category (Article 52(6)). Whether this is faster depends on your production setup and QMS; discuss it with your NB during the pre-application stage.
EUDAMED registration — obtaining your SRN, assigning a Basic UDI-DI, creating device records — does not require a completed NB certificate for most steps. Start the EUDAMED registration process during NB review, not after. Waiting until after certificate issuance to begin EUDAMED registration adds 4–10 weeks before you can legally place the device on the EU market. See the full EUDAMED registration guide for step-by-step instructions.
Commission Implementing Regulation (EU) 2026/977, published on 5 May 2026, introduces binding maximum timelines for NB conformity assessment from 25 February 2027: 30 days for application review and contract, 120 days for the QMS audit, 90 days for technical documentation assessment, and 20 days for the decision and certificate. It also limits how many times the clock can be stopped per stage and, from 1 January 2028, requires NBs to publish annual reports on timelines and median costs. From February 2027, this makes unjustified NB delays legally constrained for the first time.
Yes, but switching resets the timeline. You must withdraw the application from the current NB, transfer documentation to the new NB, and the new NB performs a full application review from scratch — previous assessment work is not transferred. This typically adds 6–12 months to total certification time. Switching is only advisable if the original NB has materially delayed without justification, or if a fundamental scope mismatch is identified. The practical answer for most manufacturers: switching is a last resort, not a speed strategy.
From February 2027, IR 2026/977 introduces binding maximum timelines that will make unjustified delays legally constrained — making switching less likely to be necessary for new contracts.
In the Commission's notified body survey of March 2026, 62% of NBs reported 13–18 months to issue a new MDR QMS certificate, and 51% reported 13–18 months for QMS plus product certificates (31% reported 19–24 months). Class III and implantable Class IIb devices typically take longer. At the most in-demand NBs, an additional 6–12 month intake queue before formal review adds to the total. Applications submitted in mid-2026 should plan for certification completion in late 2027 at earliest.
Three factors cause most delays: (1) starting NB selection too late — intake queues at constrained NBs add 6–12 months before review even begins; (2) incomplete technical file — each NB information request pauses the review clock; (3) scope mismatch — applying to an NB whose designation does not cover your device type, forcing a restart. The first and third are preventable with early NB matching using AFINA.
For Class IIa devices, NSAI, GMED, and DNV are generally accessible with shorter intake queues in 2026. BSI is the only NB with officially published lead times — their data shows Class IIa technical documentation assessment typically under 1 month, with total certification in 13–18 months. See the NB Capacity Tracker 2026 for current acceptance status across 8 major NBs.
Yes, but switching resets the assessment timeline — previous work is not transferred. The new NB performs a full review from scratch, typically adding 6–12 months. Switching is only advisable if the original NB has materially delayed without justification or if a fundamental scope mismatch is identified. From February 2027, IR 2026/977 introduces binding maximum timelines, making unjustified NB delays legally constrained for new contracts.
No — submitting formal applications to multiple NBs simultaneously is not permitted under MDR. Only one NB may hold an active conformity assessment contract for a given device at a time. However, requesting quotes and pre-application information from multiple NBs before signing a contract is recommended to compare scope, timelines, and costs.
Find a Notified Body with current capacity — start today
Submit one request on AFINA describing your device class and scope. the scope can be matched with Notified Bodies with current intake availability — receive structured responses with timelines and next steps, without cold outreach or manual EUDAMED searches.
Send us the product details and we will tell you the next compliance step.